Novo Nordisk’s Older Era Weight-Loss Drug Saxenda Related With Decreased Bone Mass Density, Research ShowsIn a brand new examine printed within the JAMA Community Open medical journal, Novo Nordisk A/S’s (NYSE:NVO) Saxenda (liraglutide), an earlier-generation weight reduction drug, reveals important declines in bone density amongst sufferers within the hips, backbone, and forearm.The examine, led by Signe Sørenson Torekov of Copenhagen College, means that whereas these medicines successfully scale back weight, they might compromise bone well being as a result of caloric restriction and hormonal adjustments.195 contributors have been randomized, with 48 contributors within the train group, 49 within the liraglutide group, 49 within the mixture group, and 49 within the placebo group.The entire estimated imply change in weight reduction through the examine was 7.03 kg within the placebo group, 11.19 kg within the train group, 13.74 kg within the liraglutide group, and 16.88 kg within the mixture group.The statement that bone mass density (BMD) decreased with liraglutide alone however not together with train helps utilizing train with weight problems medicines in populations with lowered bone mass (e.g., after menopause).The low-calorie eating regimen elevated P-CTX, the marker of bone resorption (destruction of bone tissues), by 27% and P-P1NP, the marker of bone formation, by 7%.From week 26, P-CTX decreased once more in all therapy teams, reflecting extra steady physique weight improvement. No adjustments in P-P1NP have been noticed in any lively therapy group in contrast with placebo, suggesting that bone formation was not suppressed regardless of the concomitant weight reductions.Bloomberg notes that the discovering raises alarms about related results in newer, stronger therapies like Wegovy and Eli Lilly And Co’s (NYSE:LLY) Zepbound, which induce higher weight reduction.The examine notes that regardless of a considerable weight lack of 16.9 kg for the mixture group vs 7.0 kg for the placebo group, the mixture therapy preserved site-specific BMD in contrast with placebo.Thus, within the mixture group, the preserved bone mass was noticed regardless of a weight discount of a magnitude that’s clinically related within the context of novel incretin-based weight problems therapies, similar to semaglutide and tirzepatide, which resulted in weight losses of round 15% to 19% in a scientific evaluate.Worth Motion: NVO shares have been up 3% to $146.55 on the final examine on Tuesday.Photograph by way of Shutterstock”ACTIVE INVESTORS’ SECRET WEAPON” Supercharge Your Inventory Market Sport with the #1 “information & the whole lot else” buying and selling software: Benzinga Professional – Click on right here to begin Your 14-Day Trial Now!Get the most recent inventory evaluation from Benzinga?Story continuesThis article Novo Nordisk’s Older Era Weight-Loss Drug Saxenda Related With Decreased Bone Mass Density, Research Exhibits initially appeared on Benzinga.com© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.